About TWOCELLS

We aim to become "a global company of the 21st century that contributes to world’s healthcare and people's health through regenerative medicine."
In other words, there are four pursuits.

We are a venture business company dedicated to regenerative medicine technologies to utilizing Mesenchymal Stem Cells (MSCs), which are taken from an adult body.
Since we have started our business, when regenerative medicine is not well-known, we have been engaging in developments of regenerative medicine products with MSCs for more than 20 years.

Our team have common passion (“Kokorozashi” in Japanese), which lies in “provide regenerative medicine as novel treatment options for patients with unmet medical needs.

Our Phase 3 clinical trials of gMSC1 ended in suggesting efficacy by structural evaluations with MRI and arthroscopy, although its primary endpoint failed in significance.

We of course assume that it not so easy to get an approval, for the possibility to be needed to obtain additional clinical data to discuss with regulatory authorities.

Even though, we keep on trying development of gMSC®1 to fulfill the unmet medical needs (UMNs) with our “Kokorozashi,” aiming to realize our management philosophy to become "a global company of the 21st century that contributes to world’s healthcare and people's health through regenerative medicine."

To realize our “Kokorozashi” with business growth and corporate independence, we tackle our missions.

TWOCELLS aims to be a value-creation company with "Integrated R・D・M Systems" that unitarily include Research, Development, and Marketing of MSCs-derived regenerative medicine products.

The TWOCELLS’ logo symbolizing “two cells” and “infinity” represents two founders who established TWOCELLS, and the limitless possibilities of medical technologies and the great hope that they bring.